Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

@article{Turner1998EffectOI,
  title={Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)},
  author={Robert C. Turner and Rury R. Holman and Irene M. Stratton and Carole A. Cull and David R. Matthews and Susan E Manley and V Frighi and David W. Wright and Andrew Neil and Eva M. Kohner and Helen Mcelroy and Caroline S Fox and D. R. Hadden and Grp Ukpds.},
  journal={The Lancet},
  year={1998},
  volume={352},
  pages={854-865}
}
BACKGROUND In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks. This study investigated whether intensive glucose control with metformin has any specific advantage or disadvantage. METHODS Of 4075 patients recruited to UKPDS in 15 centres, 1704 overweight (>120% ideal bodyweight) patients with newly diagnosed type 2 diabetes, mean age 53 years, had… Expand
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared. Expand
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
TLDR
The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions, and each of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. Expand
The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
TLDR
Metformin, as adjunct to intensive insulin therapy, was associated with a reduction in the total daily insulin dose and a significant weight loss in patients with type 1 diabetes mellitus. Expand
Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
TLDR
Insulin is the drug of choice for glycaemic control in CVD patients with chronic kidney disease, severe heart failure or other acute clinical conditions, and the safety of GLP-1 analogues and SGLT-2 inhibitors is still under investigation. Expand
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
TLDR
Administration of metformin, either as monotherapy or in combination with a sulfonylurea drug, improved glycemic control and led to a decrease in several CVD risk factors in patients with type 2 diabetes. Expand
A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
TLDR
Given the 4 decades of clinical experience with metformin, its antihyperglycaemic efficacy and benefits against Syndrome X, met formin offers a very favourable risk-benefit assessment when compared with the chronic morbidity and premature mortality among patients with type 2 diabetes mellitus. Expand
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
TLDR
The more pronounced improvement in indicators of insulin sensitivity by pioglitazone, as compared with metformin monotherapy in patients recently diagnosed with type 2 diabetes who are OAM-naive, may be of interest for further clinical evaluation. Expand
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
TLDR
Investigating whether metformin treatment (added to titrated insulin therapy) reduced atherosclerosis, as measured by progression of common carotid artery intima-media thickness (cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease found no effect on endothelial function. Expand
Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation.
TLDR
The evidence suggests that people newly diagnosed with type 2 diabetes mellitus and HbA(1c) > 9% should be given early TIIT to achieve normoglycaemia within weeks, after which standard care should then be adopted. Expand
Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus
TLDR
Four different bedtime insulin regimens were compared to evaluate their effects on weight gain, frequency of hypoglycemic episodes, and glycemic control in patients with type 2 diabetes whose disease was inadequately controlled with sulfonylurea therapy alone. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared. Expand
United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy
TLDR
The response to treatment with oral hypoglycemic drugs or insulin in a subgroup of patients recruited to the UKPS who continued to have marked hyperglycemia or hyperglycemic symptoms during the initial 3 months of diet therapy and in whom continued diet therapy alone was not an option is reported. Expand
UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes
TLDR
Early addition of metformin improved gly glucose control in patients with suboptimal glycemic control while taking maximum sulfonylurea therapy, irrespective of obesity or baseline FPG concentrations. Expand
U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease
TLDR
Sulfonylurea, metformin, and insulin therapies were similarly effective in improving glucose control compared with a policy of diet therapy and whether any specific therapy is advantageous or disadvantageous. Expand
Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups
TLDR
It is indicated that metformin treatment improves glycemic control, and lowers insulin resistance and risk factors for cardiovascular disease, including PAI-1, and may therefore be useful in the long-term management of NIDDM subjects who have a high risk of cardiovascular disease. Expand
Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
TLDR
The study design allowed us to evaluate the effects of metformin vs. placebo treatment on glycemic control, plasma lipid profile, HGP, insulin-mediated glucose uptake, oxidative and nonoxidative glucose metabolism, and lactate turnover and there were no changes in any of the above metabolic parameters in the placebo-treated group. Expand
UK Prospective Diabetes Study (UKPDS) XI: Biochemical Risk Factors in Type 2 Diabetic Patients at Diagnosis Compared with Age‐matched Normal Subjects
TLDR
Normal subjects aged above 65 years, had slightly higher haemoglobin A1c, insulin, C‐peptide, plasma and LDL cholesterol, triglyceride, Plasma and urine N‐acetylglucosaminidase and lower HDL cholesterol than younger subjects. Expand
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
TLDR
The ability of troglitazone to reduce insulin resistance and improves glucose tolerance in obese subjects with either impaired or normal glucose tolerance could be useful in preventing NIDDM. Expand
United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus
TLDR
The prospective data in patients with NIDDM suggest that hyperglycemia is a risk factor for cardiovascular disease, but insufficient data exist to determine whether there is a glycemic threshold for macrovascular disease. Expand
Biguanides and NIDDM
TLDR
Because metformin does not cause clinical hypoglycemia, it is actually an antihyperglycemic drug that helps combat hypertriglyceridemia, and it has been ascribed some vasoprotective properties. Expand
...
1
2
...